Q5117 Inj., kanjinti, 10 mg

Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg

• Medicare coverage: Carrier judgment
• Status: active (July 2026 file)
• MUE: max 120 units per day (practitioner), rationale: Prescribing Information